The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Astellas Pharma
Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2–positive metastatic pancreatic cancer (mPC).
 
Wungki Park
Honoraria - Ipsen
Research Funding - Astellas Pharma (Inst); Gossamer Bio (Inst); Merck (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Incyte (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Sillajen (I); SOBI; Targovax; Yiviva (I)
Research Funding - AstraZeneca/MedImmune (Inst)
 
Junji Furuse
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nihon Servier; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Otsuka; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Futoshi Kunieda
No Relationships to Disclose
 
Fei Jie
Employment - Astellas Pharma
 
Hedy L. Kindler
Honoraria - AstraZeneca
Consulting or Advisory Role - Aldeyra Therapeutics; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Deciphera; ERYTECH Pharma; Five Prime Therapeutics; Inventiva Pharma; Inventiva Pharma; ipsen; Kyowa Hakko Kirin; Merck; Paradox Therapeutics
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Polaris (Inst); Polaris (Inst); Roche/Genentech (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca